Latest news with #SrishtiGupta
Time of India
2 days ago
- Time of India
Cops who did not recognise Pkl DCP win heart, honour
Panchkula: The traffic cops deployed at a checkpoint here to prevent drink driving, who did not recognise DCP Srishti Gupta in a private vehicle and civil clothes and asked her to blow into the alco-sensor, were later honoured by the officer. They were given appreciation letters and a cash reward. The felicitation ceremony was organised at the DCP office in Sector 1 on Tuesday. It may be recalled that recently newly appointed DCP Gupta conducted a surprise inspection of the checkpoints at various places in Panchkula Sunday. During the inspection, the vigilance of the police was assessed, and the special campaign being run against drink and drive was also reviewed. The DCP Tuesday also honoured SPOs Dharamveer and Surjeet Singh, who played a key role in stopping the smuggling of illegal liquor in a Bolero vehicle, with a letter of appreciation and a cash prize. Both the jawans showed promptness and alertness while on duty at the check post and succeeded in catching the illegal liquor. The DCP also had words of praise for home guards Praveen Kumar, Kishan Singh, and Mohit Kumar, who, she said, "did excellent work at the drink and drive check posts". The three jawans played a key role in making the campaign successful by promptly issuing challans. Call DCP for misconduct, corruption: The DCP has also urged citizens to come forward with any information regarding misconduct or corruption. You can reach her directly by calling or sending a WhatsApp message to 8146630005 to report such incidents. "Your input is crucial in ensuring accountability, and confidentiality shall be maintained," said police.
Hindustan Times
6 days ago
- Hindustan Times
Haryana: Fake HSSC website busted, 6 held
Six persons involved in a fraudulent scheme centered around a fake website mimicking the official portal of the Haryana Staff Selection Commission (HSSC) have been arrested, Haryana Police said on Friday. The scam involved deceiving candidates who were attempting to register for the upcoming Common Eligibility Test (CET) 2025. According to police, the mastermind behind the fake website was arrested from Gorakhpur, Uttar Pradesh. The accused, who created and operated the fraudulent portal, was part of a larger gang that included four other suspects from Gorakhpur, along with one individual each from Kurukshetra and Fatehabad. The fake website — — was designed to look like the legitimate HSSC registration portal — The fraudulent site was hosted on a third-party domain and used QR codes to collect registration fees from unsuspecting candidates. Upon detecting the scam, the HSSC filed a formal complaint at Sector-5 police station in Panchkula. The police took immediate action under the supervision of police commissioner Sibash Kabiraj. The fake website was swiftly removed from Google and the associated QR code was deactivated to prevent further exploitation. Panchkula deputy commissioner of police Srishti Gupta, who is overseeing the investigation, confirmed that around 77 candidates were duped out of approximately ₹22,530. She urged candidates to only use official government websites with a '. domain and to avoid making payments through QR codes or UPI IDs. In an effort to intensify the investigation, the cyber police station has formed three special teams to examine mobile phones, bank accounts, and other digital evidence. DCP Gupta also warned that strict legal action would be taken against anyone exploiting the aspirations of young candidates.
Yahoo
04-06-2025
- Business
- Yahoo
Integral Ad Science Partners With Impact Plus To Empower Advertisers to Tackle Digital Advertising Emissions
Global partnership will see sustaintech platform's carbon evaluation technology integrated into IAS's platform, enabling marketers to measure their media's environmental impact alongside quality and attention metrics NEW YORK, June 4, 2025 /PRNewswire/ -- Integral Ad Science (IAS), a leading global media measurement and optimization platform, and Impact Plus, a leading sustaintech solution, announced a new partnership that will allow advertisers to track and optimize the performance and sustainability of their digital media campaigns within one platform. With legislation like the California "Climate Corporate Data Accountability Act" as well as the EU's Corporate Sustainability Reporting Directive (CSRD) regulations, which require companies to report on their environmental impact, top of mind for businesses in 2025, IAS is further bolstering its carbon calculation capabilities for advertisers by integrating Impact Plus's technology into its media quality measurement platform. The integration with Impact Plus – a global pioneer in providing advertisers with solutions to evaluate and reduce the environmental impact of their online ads – will provide advertisers with campaign-level emissions that are seamlessly incorporated into IAS reports, providing a holistic view of media metrics to drive more data-driven, sustainable advertising and allowing IAS customers to easily measure the greenhouse gas (GHG) emissions generated by their digital campaigns alongside media quality and attention metrics. "Digital advertisers are focused on reducing their carbon footprint. By providing a comprehensive view of their media's environmental impact, we can empower marketers to make more sustainable choices," said Vincent Villaret, CEO, Impact Plus. "Through this partnership with IAS, we're providing marketers with the tools they need to achieve their campaign goals without compromising their climate commitments." "IAS is a leader in providing actionable data that helps drive superior results for advertisers, and this new partnership equips Impact Plus and IAS customers with the tools for more sustainable and effective media buying globally," said Srishti Gupta, Chief Product Officer, IAS. "This is another step forward in our commitment to empower our customers and the industry to strive towards more sustainable digital media advertising while maximizing results." For more information about Integral Ad Science, visit For more information about Impact Plus, visit About Integral Ad Science Integral Ad Science (IAS) is a leading global media measurement and optimization platform that delivers the industry's most actionable data to drive superior results for the world's largest advertisers, publishers, and media platforms. IAS's software provides comprehensive and enriched data that ensures ads are seen by real people in safe and suitable environments, while improving return on ad spend for advertisers and yield for publishers. Our mission is to be the global benchmark for trust and transparency in digital media quality. For more information, visit About Impact Plus Impact Plus is an award-winning sustaintech solution that enables digital advertising players to evaluate and reduce their environmental impact. Impact Plus builds new performance indicators and solutions to help this ecosystem to use GHG emissions and electricity consumption to inform their digital advertising strategy. A pioneer since 2020, Impact Plus supports brands such as L'Oréal, Heineken, Bel Group and Engie and their agencies, to enable more sustainable media buying. Impact Plus also enables ad networks and adtech platforms including Seedtag and Microsoft Advertising, equipping them with environmental impact evaluation solutions, which can be seamlessly integrated into their delivery systems. For more information about Impact Plus, visit Media Contact: press@ View original content to download multimedia: SOURCE Integral Ad Science, Inc. Sign in to access your portfolio
Business Upturn
28-05-2025
- Business
- Business Upturn
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 166 shareholders, representing a total of 97'748'740 shares, or 43.28% of the total outstanding shares. Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update. Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented: 'On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.' The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote. The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward. The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024. The shareholders approved the amendments to the Articles of Association regarding share capital. The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius. Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026. BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026. Deloitte AG, Basel, was re-elected as the company's statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026). Notes to the editor About Idorsia Idorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10 [email protected] – [email protected] –
Yahoo
28-05-2025
- Business
- Yahoo
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 166 shareholders, representing a total of 97'748'740 shares, or 43.28% of the total outstanding shares. Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update. Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented:'On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.' The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote. The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward. The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024. The shareholders approved the amendments to the Articles of Association regarding share capital. The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius. Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026. BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026. Deloitte AG, Basel, was re-elected as the company's statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026). Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF
